J.P. Morgan Notebook, Jan. 11: Pfizer/Allergan, Celgene, Gilead And More
This article was originally published in The Pink Sheet Daily
Daily round-up of news and notes from the 2016 J.P. Morgan Healthcare Conference in San Francisco.
You may also be interested in...
With proof of high response rates in small studies of B-cell malignancies in the rear view, sponsors focus on the next hurdles – launching potentially registrational studies in 2015, honing plans for a smooth-running manufacturing process and branching out into new indications.
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.